regulatory
confidence high
sentiment positive
materiality 0.50
European patent granted covering brilaroxazine for pulmonary hypertension; adds to US, China, Japan patents
REVIVA PHARMACEUTICALS HOLDINGS, INC.
- European Patent EP3244896 granted covering brilaroxazine for treating PH, PAH, including PH in COPD or SCD patients.
- Similar patents already granted in United States, China, and Japan for brilaroxazine in PH/PAH.
- Brilaroxazine has Orphan Drug Designation from FDA for treatment of pulmonary arterial hypertension.
- CEO cites anti-inflammatory/antifibrotic activity in animal models; plans to evaluate PH/PAH expansion.